Literature DB >> 28304229

Antidrug Antibodies in Patients Treated with Alirocumab.

Eli M Roth1, Anne C Goldberg2, Alberico L Catapano3, Albert Torri4, George D Yancopoulos4, Neil Stahl4, Aurélie Brunet5, Guillaume Lecorps6, Helen M Colhoun7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28304229     DOI： 10.1056/NEJMc1616623

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

Review 1.  Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.

Authors:  Rita Del Pinto; Davide Grassi; Giuliana Properzi; Giovambattista Desideri; Claudio Ferri
Journal:  High Blood Press Cardiovasc Prev       Date:  2019-06-24

2.  Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning.

Authors:  Derek M Mason; Simon Friedensohn; Cédric R Weber; Christian Jordi; Bastian Wagner; Simon M Meng; Roy A Ehling; Lucia Bonati; Jan Dahinden; Pablo Gainza; Bruno E Correia; Sai T Reddy
Journal:  Nat Biomed Eng       Date:  2021-04-15       Impact factor: 25.671

3.  Do PCSK9 inhibitors reduce cardiovascular events?

Authors:  Michael R Kolber; Tony Nickonchuk; Ricky Turgeon
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

4.  Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons.

Authors:  Navkaranbir S Bajaj; Nirav Patel; Rajat Kalra; Amier Ahmad; Anand Venkatraman; Garima Arora; Pankaj Arora
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2018-04-01

Review 5.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

6.  Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study.

Authors:  Dirk J Blom; Johannes Breedt; Lesley J Burgess; Iftikhar O Ebrahim; Graham Ellis; Prashilla Soma; Eugene van der Walt; Poobalan Naidoo; Alet van Tonder; Frederick J Raal
Journal:  Cardiovasc J Afr       Date:  2019-09-11       Impact factor: 1.167

Review 7.  PCSK9 signaling pathways and their potential importance in clinical practice.

Authors:  Michał Wiciński; Jarosław Żak; Bartosz Malinowski; Gabriela Popek; Grzegorz Grześk
Journal:  EPMA J       Date:  2017-08-14       Impact factor: 6.543

8.  Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

Authors:  Dirk Müller-Wieland; Lawrence A Leiter; Bertrand Cariou; Alexia Letierce; Helen M Colhoun; Stefano Del Prato; Robert R Henry; Francisco J Tinahones; Lisa Aurand; Jaman Maroni; Kausik K Ray; Maja Bujas-Bobanovic
Journal:  Cardiovasc Diabetol       Date:  2017-05-25       Impact factor: 9.951

9.  Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.

Authors:  Harold E Bays; Robert S Rosenson; Marie T Baccara-Dinet; Michael J Louie; Desmond Thompson; G Kees Hovingh
Journal:  Cardiovasc Drugs Ther       Date:  2018-04       Impact factor: 3.727

10.  Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.

Authors:  Lawrence A Leiter; Bertrand Cariou; Dirk Müller-Wieland; Helen M Colhoun; Stefano Del Prato; Francisco J Tinahones; Kausik K Ray; Maja Bujas-Bobanovic; Catherine Domenger; Jonas Mandel; Rita Samuel; Robert R Henry
Journal:  Diabetes Obes Metab       Date:  2017-10-10       Impact factor: 6.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.